We also aimed to determine whether chronic treatment with a palmitoylated PrRP analog administered peripherally can influence obesity and IR as well as Tau phosphorylation, neurogenesis, synaptogenesis, and neuroinflammation in the hippocampus, as it is the first brain structure affected by neurodegenerative changes. The gene discussed is MAPT; the disease is Obesity.